Table 2. Countries without previous rounds of MDA for LF.
| Country | Primary vector | Treatment α | At-risk population, 2012 ¤ | Population growth rate, 2012 ¥ | Scale-up schedule ± | Delay § |
|---|---|---|---|---|---|---|
| Angola | Anopheles | IVM + ALB | 12,090,000 | 3.1% | -/2/1/0 | 4 |
| Brunei Darussalam | Culex * | DEC + ALB | 15,000 | 1.4% | -/2/1/0 | 1 |
| Chad | Anopheles | IVM + ALB | 7,270,000 | 3.0% | -/2/1/0 | 4 |
| Central African Republic | Anopheles | IVM + ALB | 3,300,000 | 3.1% | -/2/1/0 | 4 |
| Equatorial Guinea | Anopheles | IVM + ALB | 420,000 | 2.8% | -/2/1/0 | 1 |
| Eritrea | Anopheles | DEC + ALB | 3,577,000 | 3.3% | -/2/1/0 | 4 |
| Gabon | Anopheles | IVM + ALB | 1,290,600 | 2.4% | -/2/1/0 | 1 |
| Guinea | Anopheles | IVM + ALB | 6,067,135 | 2.6% | -/2/1/0 | 1 |
| New Caledonia | Aedes | DEC + ALB | 12,378 | 1.6% | -/2/1/0 | 1 |
| Palau | Aedes | DEC + ALB | 20,044 | 0.7% | -/2/1/0 | 1 |
| Republic of the Congo | Anopheles | IVM + ALB | 2,600,000 | 2.6% | -/2/1/0 | 1 |
| São Tomé and Príncipe | Anopheles | DEC + ALB | 410,000 | 2.7% | -/2/1/0 | 1 |
| South Sudan | Anopheles | IVM + ALB | 1,659,558 | 4.3% | -/2/1/0 | 4 |
| Sudan | Anopheles | IVM + ALB | 19,893,779 | 2.1% | -/2/1/0 | 4 |
| The Democratic Republic of Congo | Anopheles | IVM + ALB | 49,140,000 | 2.7% | -/2/1/0 | 4 |
| The Gambia | Anopheles | IVM + ALB | 1,200,000 | 3.2% | -/2/1/0 | 1 |
| Zambia | Culex | DEC + ALB | 8,780,000 | 3.2% | -/2/1/0 | 4 |
| Zimbabwe | Culex | DEC + ALB | 6,000,000 | 2.7% | -/2/1/0 | 4 |
*Treatment durations for Culex spp. were used for countries in which primary vector species was unknown.
αTreatment assumed to occur once annually using diethylcarbamazine citrate (DEC) and albendazole (ALB), or in areas co-endemic with onchocerciasis, ivermectin (IVM) and albendazole (ALB)
¤ Preventive Chemotherapy Databank Lymphatic Filariasis [Internet]. WHO. 2015 [cited 2015 January 20]. Available from: http://www.who.int/neglected_diseases/preventive_chemotherapy/lf/en/.
¥ United Nations, Department of Economic and Social Affairs, Population Division (2013). World Population Prospects: The 2012 Revision, Key Findings and Advance Tables. Working Paper No. ESA/P/WP.227.
± Refers to MDA schedules assumed to be used by these countries for the purposes of our analysis for the global elimination scenario, eradication I, eradication II, and eradication III scenarios, respectively. In schedule I, two deciles (20%) of the at-risk population are added to the MDA schedule annually. In schedule II, one decile is added annually. In schedule III, one decile is added every 2 years, and in schedule IV, one decile is added every 3rd year (see: Rate of Scale-Up and History of Control). ‘-‘ refers to a continued absence of an MDA program. ‘0’ refers to instantaneous scale-up.
§A 4-year delay was assumed for countries that have not completed LF mapping, while a 1-year delay was assumed for those that have completed mapping but have not previously carried out MDA.